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Abstract
Opiates are powerful drugs to treat severe pain, and act via mu opioid receptors distributed throughout the nervous
system. Their clinical use is hampered by centrally-mediated adverse effects, including nausea or respiratory
depression. Here we used a genetic approach to investigate the potential of peripheral mu opioid receptors as targets
for pain treatment. We generated conditional knockout (cKO) mice in which mu opioid receptors are deleted
specifically in primary afferent Nav1.8-positive neurons. Mutant animals were compared to controls for acute
nociception, inflammatory pain, opiate-induced analgesia and constipation. There was a 76% decrease of mu
receptor-positive neurons and a 60% reduction of mu-receptor mRNA in dorsal root ganglia of cKO mice. Mutant
mice showed normal responses to heat, mechanical, visceral and chemical stimuli, as well as unchanged morphine
antinociception and tolerance to antinociception in models of acute pain. Inflammatory pain developed similarly in
cKO and controls mice after Complete Freund’s Adjuvant. In the inflammation model, however, opiate-induced
(morphine, fentanyl and loperamide) analgesia was reduced in mutant mice as compared to controls, and abolished
at low doses. Morphine-induced constipation remained intact in cKO mice. We therefore genetically demonstrate for
the first time that mu opioid receptors partly mediate opiate analgesia at the level of Nav1.8-positive sensory
neurons. In our study, this mechanism operates under conditions of inflammatory pain, but not nociception. Previous
pharmacology suggests that peripheral opiates may be clinically useful, and our data further demonstrate that Nav1.8
neuron-associated mu opioid receptors are feasible targets to alleviate some forms of persistent pain.
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Introduction
Opiates such as morphine, acting at mu opioid receptors,
represent the most widely used drugs for the management of
severe pain. The three mu delta and kappa opioid receptors
are major receptors for analgesia and are expressed at central
and peripheral sites within the pain control circuits. Opioid
receptors are also largely distributed in other neural pathways
where they regulate reward and affective states [1-3]. Opioid
receptors have been shown to inhibit pain transmission in
ascending pain pathways including primary afferent fibers [4]
synapsing second order neurons in the spinal cord as well as in
the 'pain matrix' in the brain where pain messages are
integrated [5]. Opioids also regulate descending inhibitory pain
pathways by recruiting receptors in periacqueductal grey and
rostral ventral medulla [5,6].
A major issue for pain alleviation by opiates is the
manifestation of side effects including constipation, nausea as
well as development of tolerance and addiction, often leading
to arrest of treatments [7,8]. Furthermore, combined
pharmacology and knockout approaches have confirmed that
the molecular targets for the analgesic and side effects of the
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clinically used opiates are the mu receptors, encoded by the
Oprm1 gene [9]. Hence, drug treatments targeting opioid
receptors outside the central nervous system are considered
as a potential therapeutic strategy to limit centrally mediated
side effects, and first trials using peripherally acting mu
agonists at preclinical and clinical levels have been promising
[4]. However, the significance of peripheral mu receptors in
opiate-induced analgesia has not yet been investigated by
gene knockout approaches.
In this study we examined the contribution of peripheral mu
receptors to pain control using a conditional mouse knockout
approach [10]. Primary nociceptive neurons comprise several
cell populations [11] expressing Nav1.8 channels [12]. To
delete mu opioid receptors in these sensory neurons, we first
generated a mouse line harboring a floxed mu receptor gene.
This floxed mu receptor mouse line was then crossed with a
well-characterized mouse line expressing Cre recombinase in
primary afferent Nav1.8 neurons including unmyelinated C,
thinly myelinated Aδ, low-threshold mechanoreceptors and
some Aβ fibers [13,14]. Recently, by using a similar approach,
we have identified delta opioid receptors expressed by these
same primary afferent neurons as major contributors to delta-
agonist induced analgesia [15]. The present study shows that
deletion of mu receptors in peripheral Nav1.8 sensory neurons
decreases mu opiates-induced analgesia in inflammatory pain
situation but not in acute nociception assays.
Materials and Methods
Ethics statement
All experiments were carried out in accordance with the
European Communities Council Directive of 22 September
2010 (directive 2010/63/UE), with the guidelines of the
Committee for Research and Ethical issues of IASP published
in PAIN, 1983; 16:109-110, and were approved by the local
ethical committee (Com’Eth, Comité d’Ethique pour
l’Expérimentation Animale IGBMC-ICS, license N° 2010-003).
Animals
The animals were bred and maintained in IGBMC. They
were kept at 21-23°C and were provided with standard mouse
chow and water ad libitum under a 12h light-dark cycle.
Experiments were performed on male and female mice aged
between 8 to 16 weeks. All behavioral testing was performed
with the observer blind to the genotype or treatment.
Oprm1 floxed mice
We generated mice with a floxed mu opioid receptor gene
(Oprm1fl/fl) where exon 2 and 3 are flanked by a loxP site
(upstream) and a floxed hygromycin-resistance cassette
(downstream) (see Figure 1A). A 6.8 kb genomic clone (SalI/
SpeI) containing exons 2 and 3 of Oprm1 gene was isolated
from 129Sv genomic DNA and cloned into pBluescript plasmid
to generate the targeting vector. This clone was engineered to
introduce a loxP site 600 bp upstream of exon 2, and
sequenced to verify loxP sequence. In order to increase the
homologous regions surrounding the targeted locus, the
construct was extended in the 3’ direction with a 3.5 kb SpeI-
SacI fragment isolated from another mu receptor genomic
clone containing a region downstream of exon 3. A vector
containing the floxed hygro cassette was obtained from D.
Metzger (IGBMC, Illkirch, France). The hygro cassette was
removed from the cloning vector using NotI and SalI, and the
fragment filled in using the Klenow fragment to generate blunt
ends. Similarly, the targeting construct was digested with SpeI,
blunted and the floxed hygro cassette ligated into the open site.
The final 12.5 kb construct were checked by restriction and
sequence analysis before being linearized for electroporation
into 129Sv derived embryonic stem (ES) cells, which were
selected with hygromycin. Surviving cells were screened for
homologous recombination by Southern blotting with MfeI
digests and using a 3' external probe (Figure 1A,B). Positive
cells were transfected with a Cre recombinase-expressing
plasmid for removal of the floxed-Hygro cassette. ES cells with
the correct genotype were injected into C57BL/6J blastocysts,
and resulting chimeric males were bred with C57BL/6J females
to obtain germline transmission. F1 heterozygous Oprm1fl/+
mice were intercrossed to generate the homozygous Oprm1fl/fl
mouse line (50% C57BL/6J-50% 129Sv genetic background).
We verified that Oprm1fl/fl mice show intact mu receptor
expression by using a [3H]-DAMGO radioligand binding and a
mu opioid agonist-stimulated [35S]-GTPγS binding assays on
brain membrane preparations [15]. The mu opioid ligand [3H]-
DAMGO bound similarly to brain membrane preparation from
wild type and Oprm1fl/fl mice, as shown by comparable Kd (1.53
± 0.18 nM wild-type; 2.04 ± 0.31 nM Oprm1fl/fl, respectively) and
Bmax (108 ± 11 pmol/mg protein wild-type; 109 ± 6 pmol/mg
protein Oprm1fl/fl, respectively) values. DAMGO induced a
similar dose-dependent increase of [35S]-GTPγS binding in
preparations from the two genotypes (EC50 315± 31 and 331 ±
44 nM; Emax 178 ± 7% and 175 ± 5% of basal activity,
respectively), indicating that insertion of LoxP sites did not
disrupt gene transcription. Oprm1fl/fl mice were maintained for 5
generations on the 50% C57BL/6J-129Sv genetic background
until crossing with Nav1.8-Cre mice.
Conditional Nav1.8-Oprm1-/- knockout (mu-cKO) mice
In order to delete mu receptors specifically from peripheral
nociceptive neurons, we crossed the Oprm1fl/fl mice with
Nav1.8-Cre mice (100% C57BL/6J genetic background) that
express Cre recombinase in Nav1.8 positive neurons [13]. F1
mice (75% C57BL/6J-25% 129Sv) were backcrossed to
Oprm1fl/fl mice (50% C57BL/6J-50% 129Sv) to generate F2
mice (62.5% C57BL/6J-37.5% 129Sv). F2 mice homozygous
for floxed Oprm1 allele and heterozygous for Nav1.8-Cre were
selected and further bred to produce experimental cohorts
containing 50% conditional knockout animals (Nav1.8-Oprm1-/-,
referred as to mu-cKO throughout the study) and 50%
littermate control animals (referred as to mufl throughout the
study) that were on the same 62.5% C57BL/6J-37.5% 129Sv
genetic background. As genetic background represents an
important factor influencing pain assays [16], the conditional
knockout mice (mu-cKO) mice and Cre-negative controls (mufl)
used in the study were littermates harboring the same genetic
background. Genotyping of animals was done using PCR from
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Figure 1.  Generation of mu opioid receptor conditional knockout mice.  (A) The conditional Oprm1 (Oprm1fl) allele was
created by homologous recombination. The scheme shows the wild-type Oprm1 allele, the targeting vector, targeted allele and
conditional allele obtained after excision of Hygror by a Cre recombinase treatment of ES cells. The Oprm1fl conditional allele - or
“floxed” allele - harbors two loxP sites flanking the Oprm1 exon 2 and 3. Black boxes, exons; Mf, Mfe1; Sa, SalI, Sp, Spe1 restriction
sites; white triangles, loxP sites; Hygro box, floxed hygromycin-resistance cassette, grey box, probe for Southern blot analysis. Dash
lines indicate expected labeled DNA fragments in Southern blot analysis. (B) Southern blot analysis of wild-type and targeted alleles
in ES cells. Genomic DNA was digested using Mfe1 and hybridized to a 3’ external probe, shown in 1A. The expected bands at 8.5
and 15.7 kb were obtained. (C) Conditional mutant mice. Right part shows the Oprm1fl conditional allele and excised allele (deletion
of exons 2 & 3) after intercrossing Oprm1fl/fl mice with Nav1.8-Cre mice. A and B indicate PCR primers used to detect gene excision,
and C & D PCR primers for the floxed allele. PCR shows exon 2-3 deletion in DRGs but not brain of mu-cKO mice. In DRGs, the
two bands result from gene excision in Nav1.8+ neurons but not in other Nav1.8-negative cells. Mu-KO mice show full deletion in
both DRGs and brain. (D) Conditional knockout of mu opioid receptor gene in DRGs but not brain. Quantitative RT-PCR was used
to measure Oprm1 mRNA levels from mufl, mu-cKO and mu-KO mice. Oprm1 mRNA expression was normalized to mufl control
samples, and is decreased in mu-cKO animals. Oprm1 transcripts were undetectable in DRG and brain from mu-KO animals. ★★
P<0.01, mu-cKO vs mufl controls. (E) Conditional KO of the mu opioid receptor gene occurs in small/medium DRG cells. Left,
representative in situ hybridization on DRG sections from mufl, mu-cKO and mu-KO mice. Thin, medium and large arrows point to
small, medium and large cells, respectively. Scale bar = 100 µm. Right, cell size distribution of Oprm1-positive neurons in DRGs.
The % of Oprm1-positive neurons in control and mu-cKO DRGs are shown in white and black, respectively. The % of Oprm1-
positive cells is significantly reduced in small and medium, but not large diameter (>700 µm2) neurons from mu-cKO mice. ★★★
P<0.001 mu-cKO vs mufl controls, Student t-test.
doi: 10.1371/journal.pone.0074706.g001
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tail genomic DNA for Nav1.8-Cre allele as previously described
[15].
Global CMV-Oprm1-/- knockout (mu-KO) mice
To evaluate whether LoxP sites in Oprm1fl/fl mice were
functional in vivo, we bred Oprm1fl/fl mice (50% C57BL/6J -50%
129Sv) with CMV-Cre mice (100% C57BL/6J) that express Cre
recombinase under the cytomegalovirus promoter [15], leading
to germline deletion of Oprm1 exon-2 and 3. These mice,
referred as to mu-KO, were on a 75% C57BL/6J -25% 129Sv
background and used as controls for molecular studies. Mu-KO
animals showed a complete deletion of exon 2 and 3 in
genomic DNA from both brain and DRGs (Figure 1C). Mu
opioid agonist-induced G protein signaling ([35S]-GTPγS
binding assay) was undetectable in these full-KO mice (not
shown). Conventional Oprm1 knockout animals [17] were also
used in the tail immersion, hot plate, and capsaicin assays to
verify the selectivity of morphine for the mu receptor in these
tests.
Analysis of Oprm1 gene inactivation in mu-cKO mice
We used PCR on genomic DNA to test for Oprm1 exon 2
and 3 deletion in DRG and brain from mu-cKO mice by using
the Oprm1 forward primers A (5’-
ACCAGTACATGGACTGGATGTGCC-3’) and C (5’-
GTTACTGGAGAATCCAGGCCAAGCC-3’) and reverse
primers B (5’-TGCTAGAACCTGCGGAGCCACA-3’) and D (5’-
CGCTTGGGAATATCTTGTACCTATGACCA-3’) for the
excised and intact bands, respectively.
In situ mRNA hybridization
Percentages of neurons expressing Oprm1 transcripts in
DRGs from mufl and mu-cKO mice were determined by in situ
mRNA hybridization. DRG were isolated and snap-frozen in dry
ice. In situ hybridization using non-radioactive Dig-dUTP
labeled antisense and sense Oprm1 probes as control were
performed on cryostat sections of DRG (14 µm) as described
previously [15]. The Oprm1 probe (608 bp) encompassed most
of exon 2 and 3 sequences. Pictures from epifluorescence
microscope were taken using a coolSNAP camera, and image
analysis was done using ImageJ. The number of positive cells
was determined on representative transverse sections of
DRGs. Mean diameters were determined for neurons showing
a cross-sectioned nucleus. Per genotype, 1200 cells from 2
animals were analyzed from naïve animals (Figure 1E). For
inflamed animals, 850 cells from ipsilateral DRGs per each
genotype from 2 animals were analyzed.
Quantitative RT-PCR
Quantitative RT-PCR was performed as described [15] on
brains or pooled DRG from individual mice. Briefly, total RNA
was extracted using TRIzol (Invitrogen, Cergy Pontoise,
France). RNA were evaluated using a ND-1000 Nanodrop
spectrophotometer and gel eletrophoresis. Total RNA (1 µg)
from each DRG pool was reverse-transcribed in a final volume
of 20 µl. Real-time PCR was performed on cDNA in triplicate
on a Light-Cycler-480 instrument (Roche). Primer sequences
were GACGGCCAGGTCATCACTAT (β-actin forward),
CCACCGATCCACACAGAGTA (β-actin reverse), 5’-
GAGCCACAGCCTGTGCCCT-3’ (Oprm1 forward), 5’-
CGTGCTAGTGGCTAAGGCATC-3’ (Oprm1 reverse). Relative
expression ratios (mu-cKO vs mufl) were calculated by using
actin as reference gene and the 2-ΔΔCt method to evaluate
differential expression levels.
Mu opioid agonist-stimulated [35S]-GTPγS binding
assay on spinal cord membrane
Spinal cord membranes were prepared from mu-cKO, mu-
KO and mufl control mice as described [18]. Samples were
incubated in triplicate with and without the mu opioid receptor
agonist DAMGO (10-9 to 10-4 M), for 1 hour at 25°C in assay
buffer containing 30 µM GDP and 0.1nM [35S] GTPγS
(NEG030H PerkinElmer). Non-specific binding was defined as
binding in the presence of 10 µM GTPγS, and basal binding
indicates binding in the absence of agonist.
Nociception
Nociception assays were performed as described [15,19].
Briefly, the tail immersion test was performed by immersing the
tail (5 cm from the tip) into a water bath at 48°C, 50°C and
54°C for the measurement of heat nociceptive responses. Tail
withdrawal latencies were determined, with a cut-off of 10 s.
Nociception to cold was measured by a tail immersion test in a
water bath maintained at 5°C with a cut-off time of 40 s. The
time taken by the mouse to withdraw its tail or whole body
reaction was recorded. For the analysis of tolerance to
morphine-induced antinociception, tail immersion was
measured at 52°C with a 10 s cut-off. For determining
morphine-induced antihyperalgesia in the CFA-tail model, tail
immersion was measured at 48°C with a 20 s cut-off.
Tail flick test was conducted by exposing the tail of mice to
radiant heat, using an analgesymeter (LE7306 Panlab, Bioseb,
France). Tail withdrawal latencies were determined, and a cut-
off of 20 s was set.
For the Hargreaves plantar test, the radiant heat source
(Bioseb, France) was focused on the plantar surface of the
hind paw. The time from initiation of radiant heat until paw
withdrawal was measured automatically (withdrawal latency in
sec.), with a cut-off of 20 s.
The hot plate test was performed by placing mice on the hot
plate (Bioseb, France) set at 48°C, 50°C and 54°C for the
measurement of heat nociceptive responses. Latency for the
first sign of hind paw discomfort (hind paw licking, shaking or
jumping) was recorded with a 120 s cut-off. Morphine-induced
antinociception was determined with the hot-plate set at 54°C
with a 120 s cut-off.
Mechanical nociception was conducted by applying a
gradual increasing pressure by the pressure stimulation unit
with conic tip (Randall-Selitto apparatus, Bioseb, France).
Pressure threshold of tail withdrawal were determined, with a
560 g cut-off value.
Mechanical sensitivity was determined by probing the plantar
surface of hind paws with von Frey filaments, according to the
up-and-down method. Plantar hind paw surface was stimulated
with a series of eight von Frey filaments (bending force ranging
Peripheral Mu Receptors Contribute to Analgesia
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from 0.008 to 2 g). The threshold of response was calculated
by using the up-down Excel program provided by the Alan
Basbaum’s Laboratory (UCSF, San Francisco, USA).
Acetic acid-induced visceral response (writhing) was induced
and measured as described [20] by injecting intraperitoneally
(ip) 0.1ml/10g body weight of 0.6% acetic acid in water. Acetic
acid injection produced a reaction characterized by
contractions of the abdominal musculature followed by
extension of the hind limbs. Mice were placed in individual
transparent cages and the number of writhes par mouse during
the 10 min period between 5 and 15 min after acetic acid
injection was counted.
The capsaicin test was performed as described [19]. Briefly,
1.6 µg capsaicin in 10 µl were injected subcutaneously (s.c.)
into the dorsal surface of the right mouse hind-paw. The
behavioral manifestations of nociception (paw licking and
flinching) were measured during the 10 min after capsaicin
injection.
Inflammatory pain
Complete Freund’s adjuvant (CFA, 8 µl) was applied to one
hind-paw to induce inflammatory pain, as described [15].
Mechanical allodynia was measured by using von Frey
filaments and the up-down method [21], and heat hyperalgesia
was assessed with the Hargreaves plantar test [15,22].
Spontaneous pain behavior was evaluated by scoring guarding
behavior of CFA-injected hind paw as described [23] with
modifications. Mice were placed in clear Plexiglas boxes
(7x9x9 cm) on a mesh screen and scoring began when
exploration and grooming behavior ended (15-30 min).
Guarding behavior (paw elevation time) was assessed during 3
consecutive 2 min observation periods with 30 min intervals,
and the sum of elevation time over the total 6 minutes was
calculated. Inflammatory pain was also induced by injecting 20
µl into tail and assessing heat hypersensitivity by tail immersion
at 48°C as described [24].
Morphine-induced constipation
Measures for morphine-induced constipation was adapted
from previous studies [25,26]. Transit of the small intestine was
measured using the charcoal test. Six hours before testing,
animals were fasted with free access to water. Mice received
an injection of morphine or saline 20 min prior to oral gavage
with a charcoal meal containing an aqueous solution of 5%
charcoal (C3345, Sigma-Aldrich) and 2.5% arabic acid (A3006,
Sigma-Aldrich). After 30 min, mice were euthanized by cervical
dislocation and the small intestine dissected out. The distance
travelled by the leading edge of charcoal was measured
relative to the total length of the small intestine. The % of
gastrointestinal transit was calculated as (charcoal distance/
small intestine length) X 100. For analysis of fecal boli
accumulation, mice were provided water and food ad libitum
prior to the test. Mice were injected s.c. with morphine or saline
and individually placed in an empty cage with a wired mesh.
Fecal boli were collected on the paper beneath and weighed 4
h after injection.
Administration of opiates
Morphine chlorhydrate (Francopia, Gentilly, France) in saline
or saline control solution were injected ip for tail immersion, tail
flick and tail pressure tests and subcutaneously (sc) for the
acetic acid writhing tests, and animals tested 30 min later.
Morphine or saline was injected ip 45 min before the hot plate
test. In inflammatory pain experiments, morphine, fentanyl
(F-3886, Sigma-Aldrich) and loperamide (L-4762, Sigma-
Aldrich) were assayed 48 hours post-CFA, when inflammatory
pain was well established. Morphine was injected ip for
evaluation of systemic activity and mice tested 45 minutes later
in the Hargreaves and then Von Frey filaments assays.
Fentanyl (Sigma-Aldrich, France) was injected sc for
assessment of systemic activity, and mice tested 15 min later.
To test for naloxone methiodide (NM, N-129, Sigma-Aldrich)
under CFA pain, the opioid antagonist was injected ip 20 min
before sc morphine and analgesia was investigated 45 min
after morphine injection. For testing local administration of NM,
48 hours post-CFA naloxone methiodide was administered
intraplantarly (i.pl. 5 µg) into the CFA-injected hind paw in a 5
µl volume followed 1 min later by sc loperamide and test for
analgesia 20 minutes later.
Chronic morphine protocol for tolerance to
antinociception
The induction and measure of tolerance to analgesia were
performed as described [27]. Mice were injected ip for 4 days
twice a day (9 a.m. and 6 p.m.) with escalating doses morphine
chlorhydrate (10 to 40 mg/kg) in saline or saline control
solution. Heat nociceptive thresholds were measured by using
the tail immersion assay at 52°C. On day 5, antinociceptive
response was tested with morphine cumulative dose-
responses. Mice were given ascending doses of morphine (5,
10, 20 and 50 mg/kg s.c.) every 30 min and the tail withdrawal
latencies were assessed. The cut-off value was set at 10 s.
Statistical analysis
All data are presented as means ± sem. Comparison
between genotypes for acute nociception was analyzed with
Student’s t test. For inflammatory pain, comparison between
genotypes was performed using repeated measures ANOVA
followed by Fisher post-hoc test for individual time points when
appropriate. The analysis of opiates effects was performed
using two-way ANOVA for genotype and treatment followed by
post-hoc Fisher’s test to determine statistically significant
differences.
Results
Mice with a specific deletion of mu receptors in primary
afferent Nav1.8+ neurons
We used the Cre-Lox strategy to delete mu opioid receptors
(encoded by the Oprm1 gene) specifically in peripheral Nav1.8+
sensory neurons. We first generated a mouse line with Oprm1fl
conditional allele - or “floxed” allele - harboring two loxP sites
around Oprm1 exon 2 and 3 (Figure 1A-1B). We verified that
insertion of loxP sites into the Oprm1 gene did not modify mu
Peripheral Mu Receptors Contribute to Analgesia
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receptor expression (see Material and Methods Section). To
evaluate whether LoxP sites in Oprm1 gene are functional in
vivo, we bred Oprm1fl/fl mice with CMV-Cre transgenic mice
that express Cre recombinase throughout the mouse body.
CMV-Cre-Oprm1- (or mu-KO) animals showed a complete
deletion of exon 2 and 3 genomic DNA in both brain and dorsal
root ganglia (DRGs) (Figure 1C), indicating that the loxP sites
in Oprm1 gene were functional to produce Cre-mediated gene
deletion. In order to delete mu receptors specifically from
peripheral sensory neurons, we then crossed Oprm1fl/fl mice
with mice expressing Cre recombinase under the Nav1.8
sodium channel promoter control. This driver Nav1.8-Cre line
has been successfully used to produce the conditional
inactivation of several genes in primary afferent Nav1.8+
neurons [13,28]. We analyzed genomic DNA from homozygous
floxed animals harboring the Nav1.8-Cre transgene (mu-cKO
mice). PCR analysis showed successful excision of Oprm1
exons 2 and 3 in DRGs (Figure 1C). The floxed allele was
intact in brain of mu-cKO animals (Figure 1C).
We next compared Oprm1 gene expression in DRGs from
mu-cKO and mufl control mice. Quantitative RT-PCR analysis
showed a 60% decrease of Oprm1 mRNA in DRGs from mu-
cKO mice as compared to controls (Figure 1D, mu-cKO vs mufl
P = 0.0019) while intact expression was found in the brain. In
situ hybridization (ISH) revealed a large decrease in the
number of Oprm1-expressing neurons in DRGs from mu-cKO
mice (Figure 1E). DRGs from mu-cKO mice showed only 7%
positive cells as compared to 29% Oprm1-expressing neurons
in control mice (mu-cKO vs mufl control, P < 0.001). The
decrease in Oprm1-expressing neurons was detected in small
and medium neurons with a cell body area < 500 µm2, and was
not significant in larger neurons (Figure 1E, P= 0.18, mu-cKO
vs mufl for neurons > 500 µm2), indicating that the conditional
mu receptor knockout occurred essentially in small/medium
size neurons.
To determine if the deletion of mu receptors in primary
Nav1.8 neurons would impact on mu receptor levels in the
spinal cord, we compared mu receptor protein expression of
mu-cKO and control mufl mice by using the mu opioid agonist
DAMGO-stimulated [35S]-GTPγS binding assay on spinal cord
membrane preparations. Mu opioid receptor activation levels
were indistinguishable in spinal cords from mu-cKO and control
animals (Figure 2). We verified that we could detect a decrease
in mu receptor expression level by testing a 50%-50% mix of
spinal cord membranes from mufl and mu-KO animals. As
expected, mu receptor stimulation for this mix was half as
compared to that obtained with spinal cord membrane from mufl
animals. This finding suggests that conditional mu receptor
knockout in Nav1.8 neurons did not induce a substantial
reduction of mu receptor binding in the spinal cord.
Nociceptive thresholds are similar in mu-cKO and
control mice
We first examined the consequences of conditional mu
receptor deletion on acute pain perception. As mu receptor
activation is traditionally known to reduce the perception of
heat pain, we first compared mu-cKO and control animals in
the heat nociception paradigms that were used previously to
characterize conventional receptor KO animals [17,20,29-31].
Conditional mu-cKO mice showed no alteration of responses
to noxious heat in the tail immersion, tail flick, and hot plate
assays (Figure 3A). Under the same conditions, mu-KO (or
conventional-KO) mice displayed higher sensitivity in the hot
plate assay (Figure 3B), as previously reported [29-31]. When
cold nociception was investigated in a 5°C tail immersion
assay, mu-cKO, mu-KO and mufl animals responded with
similar tail withdrawal latencies (Figure 3A right panels). Also,
no change was found in cKO animals for response to
mechanical stimuli in von Frey filaments and tail pressure
assays, as well as responses to chemical stimuli in the
capsaicin and acetic acid-induced visceral pain assays (Figure
3C). Under similar conditions, total mu-KO mice showed
enhanced mechanical sensitivity in the Von Frey test (Figure
3D). Altogether, our results indicate that the endogenous tone
at mu receptors expressed by primary afferent Nav1.8 neurons
does not control acute pain perception to heat, mechanical and
chemical stimuli.
Morphine-induced antinociception and tolerance to
antinociception are unaltered in cKO mice
We examined morphine-induced antinociception in several
acute pain responses well known to be morphine-sensitive and
widely used for opiates analgesia [9]. As the tail flick, tail
immersion and hot plate heat pain assays may implicate
peripheral receptors to a different extend, we have investigated
the role of the targeted mu receptors in these three assays.
Morphine produced dose-dependent antinociception in the tail
flick, tail immersion and hot plate assays, which were
comparable in mu-cKO and mufl mice (Figure 4A). In vivo
morphine selectivity for mu receptor at the tested doses was
verified in conventional knockout animals (Figure 4A).
Morphine induced also similar analgesic responses in mu-cKO
and control animals for tail pressure and visceral acetic acid
writhing assays (Figure 4B). Globally, this indicates that mu
receptors expressed by Nav1.8 sensory neurons do not
contribute to systemic morphine-induced antinociception under
acute noxious conditions.
We also determined if the targeted mu receptors were
implicated in the development of tolerance to antinociception
(Figure 5). We treated mufl, mu-cKO and mu-KO mice with
repeated doses of morphine (10 to 40 mg/kg twice per day)
over 4 days to induce tolerance, and investigated at day 5
morphine-induced antinociception by using the tail immersion
assay at 52°C, as described in a recent study [27]. Control
saline mufl and mu-cKO mice displayed the same dose-
response curve for morphine-induced antinociception
(morphine ED50 in mufl 5.02 ± 1.02 mg/kg; mu-cKO 5.40 ± 1.12
mg/kg; P> 0.05 between genotypes). Chronic morphine
administration induced tolerance to antinociception, shifting
morphine dose-response curve to the right in both genotypes
(chronic morphine vs chronic saline, mufl P= 0.012; mu-cKO P=
0.03). There was no significant difference between chronic
morphine-treated mufl and mu-cKO mice (morphine ED50 in
mufl 10.01 ± 1.36 mg/kg; mu-cKO 13.09 ± 3.01 mg/kg; P> 0.05
between genotypes). Mice with the total deletion of mu receptor
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showed no antinociceptive response to morphine, as expected.
Thus, mu receptors on Nav1.8 sensory neurons do not appear
to be mainly implicated in tolerance to analgesia.
Mu opiate-induced analgesia is decreased in cKO mice
under inflammatory pain
When inflammatory pain was induced locally by injection of
Complete Freund Adjuvant (CFA) into a hind paw, mu-cKO and
mufl control mice displayed comparable thermal and
mechanical hypersensitivities 48 h post-CFA (Figure 6A and B;
0 mg/kg morphine). Also, there was no difference for
spontaneous pain as measured by guarding behavior, under
CFA-inflammation (Figure 7A). Therefore, our results indicate
that the endogenous tone at mu receptors expressed by
Nav1.8 neurons does not exert a tonic control on the
hypersensitivity induced by CFA-inflammation.
Interestingly, the peripheral mu receptor KO modified opiate-
induced analgesia under conditions of inflammatory pain.
Morphine administered by a systemic route dose-dependently
attenuated CFA-evoked hypersensitivity in control mufl animals.
However morphine was less effective in the mu-cKO mice.
Analgesia was lowered by two-fold when evaluated for heat
sensitivity, and was strongly decreased for mechanical
allodynia (Figure 6A), indicating that mu receptors on Nav1.8-
neurons contribute to morphine anti-hyperalgesic properties.
Using a pharmacological approach, we verified the peripheral
action of systemic morphine on CFA-induced hypersensitivity
under our experimental conditions. Naloxone methiodide, an
opioid antagonist that does not cross the blood brain barrier,
has been used previously to investigate peripheral opioid
receptors involvement [4]. When administered to mufl mice prior
to morphine, naloxone methiodide inhibited morphine-induced
analgesia (Figure 6C). Fentanyl, another widely used mu
opiate agonist, was also tested on cKO and mufl mice. Mu-cKO
animals showed diminished fentanyl-induced antiallodynia at
the low 0.03mg/kg dose for mechanical hypersensitivity (Figure
6B).
In order to assess the role of peripheral mu receptor at later
time-points of inflammatory pain, we induced inflammation by
CFA administration into the tail and heat sensitivity was
measured until day 9 (Figure 7B). Mu-cKO mice and floxed
controls show no difference in heat hypersensitivity at days 2, 6
and 9. Conditional KO animals had a decreased analgesic
response to morphine at day 9, indicating an implication of the
targeted receptors at this later time point, hence strengthening
the results obtained at day 2 in the paw inflammation model.
Figure 2.  Mu opioid agonist-induced [35S]-GTPγS binding is comparable on spinal cord membrane preparation from mu-
cKO and mufl mice.  Spinal cord membranes were incubated in the absence or presence of the mu opioid agonist DAMGO
(10-9-10-4 M) in assay buffer containing [35S] GTPγS. Basal level (100%) represents the specific [35S]-GTPγS binding in the absence
of agonist. DAMGO significantly increases [35S]-GTPγS binding, in a comparable manner for mu-cKO and mufl mice. [35S]-GTPγS
binding was absent on spinal cord membranes from mu-KO mice, and was decreased by half with a 50%-50% mix of membranes
from mufl and mu-KO animals, containing half mu receptors as compared to mufl membranes, indicating that this assay allows to
detect reduced receptor expression. Results are presented as means ± sem of 5-6 experiments on 5 distinct membrane
preparations. ★★★ P<0.001, ★ P<0.05 50%-50% mu-cKO, mufl or 50%-50% mix vs mu-KO, Student t-test.
doi: 10.1371/journal.pone.0074706.g002
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Figure 3.  Acute pain responses are unchanged in conditional mu-cKO mice.  (A) Acute thermal responses were similar in mu-
cKO mice and mufl controls in the tail immersion test at 48, 50 and 54°C (n=15/genotype), tail flick test (n=10/genotype), Hargreaves
test at three different intensities (n=10/genotype), hot plate test (48, 50 and 54°C, n=15 /genotype) and cold tail immersion test at
5°C (n=19/genotype). (B) In the experimental conditions of (A), mu receptor total knockout mice displayed higher sensitivity in the
hot plate assay only (conventional KO vs WT, n =11-14/genotype, ★ P<0.05) whereas they behaved as controls for heat tail
immersion (n=11-14/genotype), tail flick (n=12/genotype), Hargreaves (n=20/genotype) and cold (5°C) tail immersion (n=12-13/
genotype) tests. (C) Nociceptive responses to mechanical and chemical stimuli were unchanged in the conditional mutant mice
when assessed in the tail pressure (n = 8/genotype) or von Frey filaments (n = 10-13/genotype) test, nocifensive responses to
capsaicin (n=10/genotype) and abdominal writhing induced by acetic acid (n=13-14/genotype). (D) In the same experimental
conditions as in (C), mu receptor total knockout mice were more sensitive than control mice in the von Frey filaments test for touch
perception (conventional KO vs WT, n = 33-57/genotype, ★★ P<0.01, Student t-test). Total knockout mice behaved as controls in
the tail pressure test (n = 8/genotype), nocifensive responses to capsaicin (n=6/genotype) and abdominal writhing induced by acetic
acid (n=4/genotype).
doi: 10.1371/journal.pone.0074706.g003
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Additionally we tested the analgesic potency of the
peripherally acting mu opiate loperamide [32] in mu-cKO and
control mice using the same paw inflammation model.
Loperamide dose-dependently alleviated inflammatory
hypersensitivity in mufl mice (Figure 8). In mu-cKO mice,
2mg/kg loperamide-induced analgesia was abolished, while
analgesia was maintained at 4 mg/kg. At this 4mg/kg dose,
loperamide-induced analgesia was absent in mu-KO mice
(Figure 8A), confirming the selective action of loperamide on
mu receptors. In order to determine if loperamide would also
induce analgesia also via delta receptors, as shown by
Shinoda and colleagues in a neuropathic pain model [33], we
tested loperamide activity on delta receptor knockout mice.
Loperamide-induced analgesia was maintained in delta-
receptor KO animals (Figure 8B), demonstrating the selectivity
of loperamide for the mu receptor. We then determined
Figure 4.  Conditional mu-cKO and control mice show comparable systemic morphine analgesia in nociceptive
assays.  Top. Morphine induced dose-dependent antinociception in both mu-cKO and mufl mice in the three heat assays, (A) tail
immersion, (B) tail flick and (C) hot plate. Morphine-induced analgesia was abolished in conventional mu-KO animals (tail
immersion, n=10/genotype; tail flick, n=10-14/genotype; hot plate, n=6-17/ genotype), confirming the selective effect of morphine on
mu receptor. Bottom. Mu-cKO and mufl control mice show similar systemic morphine analgesia in the tail pressure (n=9-13/
genotype) and acetic acid-induced visceral nociceptive (n=13-14/genotype) assays. Two-way ANOVA, post-hoc Fisher test for
individual time points, ✰ P <0.05, ✰✰ P<0.01, ✰✰✰ P<0.001, morphine vs saline.
doi: 10.1371/journal.pone.0074706.g004
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whether loperamide-induced analgesia at 4 mg/kg was due to
the activation of central receptors or of peripheral mu receptors
remaining in cKO mice, by pretreating floxed animals with the
peripheral opioid antagonist naloxone methiodide. Naloxone
methiodide pretreatment blocked the 4 mg/kg loperamide-
induced analgesia (Figure 8C), indicating that remaining
peripheral mu receptors likely expressed in non-Nav1.8-
positive neurons, also contribute to the peripheral analgesia
induced by loperamide.
Mu opioid receptor expression is increased in DRGs
from inflamed mufl control but not mu-cKO mice
Our data indicate that peripheral mu receptors contribute to
morphine analgesia in an inflamed, but not naïve state.
Inflammation is known to increase expression of mu receptors
in Nav1.8 neurons [4]. One explanation for our result could thus
be that CFA indeed increases mu receptor expression in
Nav1.8 neurons from mufl animals, to levels that allow
significant morphine analgesia. In contrast, receptor levels
Figure 5.  The conditional deletion of mu receptor in
Nav1.8 primary neurons does not abrogate tolerance to
morphine-induced antinociception.  Morphine dose-
dependent antinociception was measured following repeated 4-
day i.p. injections of morphine or saline in mufl controls, mu-
cKO and mu-KO animals. The shift to right for both mufl and
mu-cKO chronic-morphine animals indicates the development
of a comparable tolerance to analgesia. Total mu-KO animals
show no antinociception. n=6-7/genotype/treatment, two-way
ANOVA (genotype x treatment F(1,30) = 19.919, P <0.001 for
treatment; F(2,30) = 97.039, P <0.001 for genotype); post-hoc
Fisher test for individual morphine doses, ✰ P <0.05, ✰✰
P<0.01, chronic morphine (tolerance) vs chronic saline in mufl
mice; ★ P<0.05, ★★ P<0.00 chronic morphine (tolerance) vs
chronic saline in mu-cKO mice.
doi: 10.1371/journal.pone.0074706.g005
would remain low in Nav1.8 neurons from mu-cKO animals,
which would be less sensitive to peripheral morphine
analgesia. In order to test this hypothesis, we evaluated the
number of mu receptor-expressing neurons in the DRGs of
both mu-cKO and mufl mice 48h after CFA, using ISH as above
(Figure 1). Inflamed mufl mice showed a strong increase in the
percentage of Oprm1-expressing neurons, in both small and
medium size cells (Figure 9), in accordance with earlier
findings [34]. In contrast, the percentage of Oprm1-expressing
cells in DRGs from inflamed mu-cKO animals was unchanged
after CFA. Therefore, morphine analgesia in mufl animals likely
results from CFA-induced increased mu receptor expression in
Nav1.8 neurons, which does not occur in the conditional
mutants.
Morphine-Induced Constipation Is Unchanged in mu-
cKO Mice
Genetic tracing experiments recently showed that some
myenteric neurons express the Nav1.8-Cre protein [35]. In
order to investigate any potential role of the targeted mu
receptors in intestinal motility, we analyzed morphine-induced
constipation by using small intestinal transit and fecal boli
accumulation assays [25]. We observed a slight tendency to
lower basal fecal boli accumulation in mu receptor total KO
mice as compared to floxed mice (Figure 10A, two-way
ANOVA for floxed and total KO mice, genotype X treatment
F(1,16) = 1.541, P = 0.2323 for genotype). A slightly lower
transit activity in conventional mu receptor KO mice has been
described earlier [26], that was proposed to be due to
compensation for the lack of mu receptor activity that normally
decreases intestinal transit. In both tests, morphine-induced
constipation occurred similarly in mu-cKO and mufl mice
whereas morphine effect was abolished in mu-KO mice (Figure
10). These data show that mu receptors expressed by Nav1.8
neurons are not implicated in morphine constipating effects.
Discussion
Both clinical and preclinical [4] studies have shown the
potential for developing peripheral mu opioid analgesics to
avoid central side effects. The implication of peripheral
receptors has been investigated mainly based on
pharmacological approaches and the use of peripheral
antagonists [36-38]. In the present study, we reproduced these
pharmacological data, and more importantly, our data provide
the first genetic demonstration for the implication of mu
receptors on primary afferent neurons in opiate-induced
analgesia.
Mu opioid receptors are expressed throughout pain-
controlling networks in the brain, in the spinal cord as well as in
sensory neurons [2,11,39]. Our conditional knockout strategy in
primary afferent Nav1.8 neurons produced a threefold
decrease in mu receptor mRNA levels and mu receptor-
expressing neurons in the DRGs where cell bodies for sensory
neurons are located. The deletion of mu receptors occurs in
small and medium diameter DRG neurons that represent the
main population of primary nociceptive neurons including C
fibers and A-delta fibers, while large diameter A-alpha/A-beta
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Figure 6.  Conditional mu-cKO mice show decreased opiate-induced analgesia in the CFA-induced inflammatory pain
model.  (A) Two days after CFA, morphine (i.p.) dose-dependently reduced heat and mechanical hypersensitivities in mufl control
mice. This analgesia was diminished in mu-cKO mice. Dashed lines represent baseline (pre-CFA) sensitivities. White bars, mufl
mice; black bars, mu-cKO mice. For plantar test, n=13-20/genotype. two-way ANOVA (genotype x treatment F(1,90) = 75.336, P
<0.001 for treatment; F(1,90) = 23.313, P <0.001 for genotype. Post-hoc Bonferroni test, ✰✰✰ P<0.001, morphine vs saline; ★★
P<0.01, ★★★ P<0.001 cKO vs flox controls. For Von Frey filaments test, n=7-18/genotype. two-way ANOVA (genotype x treatment
F(1,91) = 41.573, P <0.001 for treatment; F(1,91) = 27.378, P <0.001 for genotype. Post-hoc Bonferroni test, ✰✰ P<0.01, ✰✰✰
P<0.001 morphine vs saline; ★ P<0.05, ★★ P<0.01 mu-cKO vs mufl controls. (B) Fentanyl produced a dose-dependent analgesia
in mufl control mice 2 days after CFA. Mu-cKO mice displayed a decreased analgesic response in the mechanical sensitivity test for
the 0.03 mg/kg fentanyl dose. n=5-10/genotype. For plantar test, two-way ANOVA (genotype X treatment F(1,54) = 8.979, P <0.001
for treatment, P= 0.19 for genotype), post-hoc Bonferroni test; ✰✰ P <0.01, ✰✰✰ P<0.001, fentanyl 0.1 mg/kg vs saline; for
fentanyl 0.03 mg/kg, P = 0.0675 in mufl animals, P = 0.21 in mu-cKO animals. For Von Frey test, two-way ANOVA (genotype X
treatment F(1,45) = 22.802, P <0.001 for treatment, F(1,45) = 9.316, P <0.01 for genotype). Post-hoc Bonferroni test for treatment,
✰✰✰ P<0.001, fentanyl 0.1 mg/kg vs saline; for fentanyl 0.03 mg/kg, P = 0.0575 mufl animals, P = 0.28 mu-cKO animals. Post-hoc
Fisher test for genotype, ★ P<0.05, mu-cKO vs mufl mice. (C) Morphine-induced analgesia is reduced by systemic administration of
the peripheral antagonist naloxone methiodide (NM). Morphine (5 mg/kg) induced an antihyperalgesic effect in mufl mice for both
heat and mechanical responses. Systemic NM diminished morphine-induced analgesia. Heat hypersensitivity, one-way ANOVA for
treatment F(3,42) = 29.778, P<0.001 ; post-hoc Bonferroni test, ✰✰ P <0.01, ✰✰✰ P <0.001 morphine vs saline; ★★ P<0.01
★★★ P<0.001 NM + morphine vs morphine. Mechanical hypersensitivity, one-way ANOVA for treatment F(3,52) = 23.467,
P<0.001 ; post-hoc Bonferroni test, ✰✰✰ P <0.001 morphine vs saline; ★★★ P<0.001 NM + morphine vs morphine.
doi: 10.1371/journal.pone.0074706.g006
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Figure 7.  Spontaneous guarding pain behavior after paw-CFA and CFA-inflammatory pain at day 9 in conditional mu-cKO
mice.  (A) The effect the conditional mutation on ongoing pain behavior was evaluated by quantifying the duration of guarding
behavior over 6 min in mufl, mu-cKO and mu-KO mice before CFA-induced inflammation and at days 1 and 2 post-CFA. All mouse
lines showed the same behavior (mufl, n=14; mu-cKO, n=6; mu-KO, n=12). Results are expressed as means ± sem. ★ P<0.05, ★★
P<0.01, ★★★ P<0.001 post-CFA vs naïve. (B) Following CFA injection into tail, mu-cKO and mufl mice showed similar heat
hyperalgesia at days 2, 6 and 9. The dashed line represents baseline (pre-CFA) sensitivity in the tail immersion tests at 48°C.
Morphine (i.p.) produced anti-hyperalgesia in both genotypes, and that was reduced in mu-cKO mice as compared to controls.
n=19/genotype., two-way ANOVA (genotype x treatment F(1,71) = 48.812, P <0.001 for treatment; F(1,71) = 5.999, P <0.05 for
genotype. Post-hoc Bonferroni test, ✰✰✰ P<0.001, morphine vs saline; ★ P<0.05, cKO vs flox controls.
doi: 10.1371/journal.pone.0074706.g007
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Figure 8.  Conditional mu-cKO mice show decreased analgesia to the peripheral opiate loperamide in the paw
inflammatory pain model.  (A) Two-days after CFA, loperamide (s.c.) dose-dependently reduced mechanical hypersensitivity of
mufl control mice. Analgesia produced by 2mg/kg loperamide was diminished in the conditional mutant mice and 4mg/kg loperamide
induced no analgesia in the full mu-KO mice. Dashed lines represent baseline (pre-CFA) sensitivity. White bars, mufl mice; black
bars, mu-cKO mice; grey bars mu-KO mice; n=4-10/genotype. Two-way ANOVA for mufl and mu-cKO mice (genotype X treatment
F(1,78) = 17.508, P <0.001 for treatment; P = 0.0657 for genotype), post-hoc Bonferroni test, ✰ P <0.05, ✰✰✰ P <0.001,
loperamide vs saline. (B) Loperamide-induced antihyperalgesia was comparable in control and delta opioid receptor total KO mice;
n=9-13/genotype. White bars, control mice; stripped bars, delta receptor KO mice, two-way ANOVA (genotype X treatment F(1,38)
= 16.363, P <0.001 for treatment; P = 0.959 for genotype), post-hoc Fisher test, ✰ P <0.05, ✰✰ P <0.01, loperamide vs saline. (C)
Analgesia produced by 4 mg/kg loperamide in mufl mice was abolished by pretreatment with the peripheral antagonist naloxone
methiodide (NM); n=11/group, white bars, mufl mice; hatched bars, NM-pretreated mufl mice; one-way ANOVA for treatment F(2,42)
= 16.925, P <0.001 for treatment; post-hoc Bonferroni test , ✰✰✰ P <0.001, loperamide vs saline; ★★★ P<0.001, loperamide vs
NM + loperamide.
doi: 10.1371/journal.pone.0074706.g008
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Figure 9.  Inflammation increased the number of small/medium Oprm1-positive neurons in DRGs of mufl but not of mu-cKO
mice.  Inflammation was induced by intra-paw CFA as in previous figures. The cell size distribution of Oprm1-positive neurons in
DRGs was evaluated by In Situ Hybridization. The % of Oprm1-positive neurons in naïve mufl and mu-cKO DRGs are shown in
white and black, respectively. The % of Oprm1-positive neurons in ipsilateral DRGs of CFA mufl and mu-cKO DRGs are shown in
dotted white and black bars. ✰✰ P <0.01, ✰✰✰ P <0.001, CFA vs naïve; ★★★ P<0.001 mu-cKO vs mufl, Student t-test.
doi: 10.1371/journal.pone.0074706.g009
Figure 10.  Morphine-induced constipation is maintained in conditional mu-cKO mice.  Left: Morphine-induced inhibition of
small intestinal transit. Mice were treated with saline (0 mg/kg morphine bars) or morphine (10 mg/kg) and 20 min. later given a
charcoal gavage. For determination of small intestine transit, the distance travelled by charcoal was measured relative to the total
length of the small intestine. White bars, mufl mice; black bars, mu-cKO mice; grey bars, mu-KO mice, n=5/group, two-way ANOVA
(genotype X treatment F(2,24) = 18.206, P <0.001 for treatment; P = 0.184 for genotype), post-hoc Fisher test, ✰✰✰ P <0.001,
morphine vs saline. Right: Morphine-induced inhibition of fecal boli accumulation. Mice were administered morphine or saline and
fecal boli were collected after 4 hrs. n=10-12/group, two-way ANOVA (genotype X treatment F(2,62) = 21.138, P <0.001 for
treatment; P = 0.934 for genotype), post-hoc Fisher test, ✰✰ P <0.01, morphine vs saline.
doi: 10.1371/journal.pone.0074706.g010
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somatosensory neurons still express the mu receptor. These
findings are in accordance with the well-described conditional
deletion profile obtained with this Nav1.8-Cre mouse line
[13,14].
Mu receptor cKO mice displayed pain sensitivity similar to
control mice in all nociception assays investigated. Our results
demonstrate that enhanced sensitivity to heat pain, which was
previously observed in mu receptor conventional knockout or
knockdown animals [29-31], implicates mu receptors
expressed by cell types other than primary Nav1.8 neurons.
These could be neurons of the central nervous system (brain or
spinal cord) or Nav1.8-negative DRG neurons at the periphery.
The present data are similar to those indicating no alteration of
acute pain perception in animals with a conditional deletion of
delta opioid receptors in these same neurons [15], and differ
from those obtained with the Nav1.8-conditional deletion of
cannabinoid CB1 receptors, that showed increased sensitivities
to heat and pressure [40]. Overall endogenous cannabinoid but
not opioid systems appear to regulate acute pain perception at
the level of Nav1.8 sensory neurons. Our data also indicate
that, under basal non-chronic pain conditions, and by using
three different assays for heat pain implicating fast or delayed
responses [41], one assay for mechanical pain and one
measure of chemical pain, the targeted mu receptors on
peripheral Nav1.8 neurons are not mainly implicated in the
analgesic effects of opiates.
Further, in the CFA-induced inflammatory pain model, mu-
cKO and control mufl animals developed comparable
hypersensitivity, suggesting that mu receptors on Nav1.8
neurons are not principally involved in the tonic inhibition of
CFA-induced inflammatory pain. Mechanisms implicating
peripheral endogenous opioid tone for attenuating chronic pain
were described previously [4,15,42]. In the future, Nav1.8 mu-
cKO mice may be studied using other chronic pain models to
examine whether peripheral mu receptors contribute to
alleviate these chronic pain modalities such as neuropathies
[38,43], diabetes [44], cancer [45,46] or cancer chemotherapy
[47]. Also, peripheral mu and delta receptors may be both
needed, or act synergistically, to produce a substantial
endogenous opioid analgesia, as suggested by pharmacology
studies [48-50].
In the several acute nociception assays tested, morphine-
induced analgesia was similar in mu-cKO and control mice.
This indicates that mu receptors expressed by primary Nav1.8
neurons are not predominantly implicated in morphine-induced
antinociception. However, when morphine was tested in the
CFA-inflammatory pain model, a significant part of the
analgesia was lost in mu-cKO animals. Opiate analgesia was
also substantially reduced in mu-cKO animals for low doses of
fentanyl and loperamide, in accordance with recent
pharmacological data suggesting an implication of peripheral
mu receptor-mediated mechanisms for moderate, but not high
doses of these opiates [51-53]. Analgesia data on inflamed
mice from our genetic model, therefore, definitely establish that
mu receptors on primary afferent Nav1.8 neurons represent
key actors for systemic opiate analgesia under conditions of
inflammatory pain.
Analgesia can also be obtained following intrathecal opiate
administration that may be mediated by mu receptors on
sensory neuron terminals in the spinal cord dorsal horn, spinal
interneurons and projection neurons as well as neurons in the
brain [54-56]. The study by Mansour and colleagues [2] has
shown that spinal cord cells expressing mu receptor transcripts
are localized in laminae 4 to 10, with fewer cells in laminae 2
and 3, and several other papers report a substantial mu
receptor expression by spinal neurons by using RT-PCR
[57-59]. Following dorsal rhizotomy, 40 to 72% [60-62] of mu
receptor was lost in the spinal cord that was proposed to
correspond to the loss of presynaptic receptors and possibly
transsynaptic degenerative mechanisms. The analysis of
presynaptic receptor involvement in opiate spinal analgesia has
led to controversial results. In rats, paw inflammation and
arthritis led to an increase in mu receptor expression in DRGs
that did not translate into an augmented receptor level in spinal
cord [63,64]. Also, paradoxically, the loss of Trpv1 primary
afferent neurons obtained following resiniferatoxin treatment
produced a reduction of spinal mu receptors but a potentiation
of spinal opioid analgesia [65]. We found comparable mu
receptor expression levels in the spinal cord of mu-cKO and
control mice (Figure 2). This suggests that mu receptor
expression by local spinal neurons could hide the primary
afferent component, precluding the analysis of presynaptic
receptor involvement by simple comparison of spinal analgesia
in cKO and control animals. In the future, the role of mu
receptors expressed by the remaining small/medium or large
Nav1.8-negative DRG neurons as well as by neuronal
populations in spinal cord and brain may be elucidated by the
study of novel conditional KO mouse lines harboring a mu
receptor deletion in these other specific neurons.
Here, the deletion of the mu receptor population potentially
involved in primary nociceptive processing reveals the role of
these receptors in systemic opiate analgesia under
inflammatory condition but not in basal non-inflamed state.
Previous research has shown that chronic pain or stress lead
to enhanced opiate analgesia [36,66,67], potentially mediated
by changes in mu receptor expression, localization or activity
under these circumstances [34,63,64,68-70]. Accordingly, we
found that CFA-induced inflammation increased the number of
small and medium sized neurons expressing mu receptor in the
DRGs of control mufl mice, a phenomenon that did not occur in
the conditional mutants (Figure 9). These findings hence
suggest that the augmented mu receptor expression in control
animals during inflammation, which is absent in the conditional
mutants, contributes to opiate-induced analgesia.
In conclusion, opiate-induced analgesia can be elicited by
mu opioid receptor activation at several sites of the pain-control
pathways within the nervous system and our approach
identifies a specific mu opioid receptor population within
sensory neurons as a key player for opiate-induced analgesia
under inflammatory pain. It thus provides a strong basis for the
design of peripherally acting opiate analgesics devoid of
centrally mediated side effects [71]. Other mu receptor
populations that contribute to pain control and opiate analgesia,
in neurons other than Nav1.8 neurons and for distinct pain
modalities, remain to be characterized by genetic approaches.
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To this respect, this mu receptor floxed mouse line represents
a unique tool that, in principle, allows deletion of mu receptors
at any specific sites or neuronal type of interest within pain
pathways, using appropriate driver Cre transgenic mouse lines,
or virally-mediated Cre excision.
Of broader interest, this mu receptor floxed mouse line
constitutes an unique genetic tool that will be used to
investigate the role of specific mu receptor populations in other
pathologies of the nervous system including addiction or mood
diseases [3,72].
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